Objective:To comprehensively review the literature relating to the use of Artemisiae Argyi Folium (AAF;the dried leaf of Artemisia argyi Lévl.et Vant.from the Asteraceae family),and qi ai (AAF grown in Qichun Cou...Objective:To comprehensively review the literature relating to the use of Artemisiae Argyi Folium (AAF;the dried leaf of Artemisia argyi Lévl.et Vant.from the Asteraceae family),and qi ai (AAF grown in Qichun County and the adjacent areas in Hubei Province,China) in the field of traditional Chinese medicine.Furthermore,this study aimed to give results of the contents determination of three bioactive components in qi ai and AAF.Methods:The literature was reviewed to acquire relevant information regarding the quality and application of AAF and qi ai.In addition,the contents of the bioactive components (essential oil,total flavonoids and tannins) were determined in 29 AAF samples collected from China and Korea using the methods in the Chinese pharmacopoeia (2015) or determined by our experiments.Results:The dried leaf of A.argyi Lévl.et Vant.from the Asteraceae family is a mainstream commodity of AAF.Qi ai is a commercial type of AAF well-known for its good quality,which has been recorded in Chinese ancient literature.Modern research has showed that more intense heat with stronger penetration was generated in moxibustion therapy when qi ai moxa stick was burnt compared with general moxa stick,which led to a better curative effect.Our research also showed that the contents of essential oil,total flavonoids and tannin in qi ai were significantly higher than those of general AAF samples.Conclusion:The superior quality of qi ai compared with general AAF may be due to relatively higher contents of bioactive components.This study provides basic information for further study and utilization of AAF and qi ai.展开更多
Increased serum urotensin Ⅱ(UⅡ) levels in human cirrhotic populations have been recently shown,but the long-term effects of UⅡ receptor antagonist on the cirrhosis have not been investigated.To investigate the ther...Increased serum urotensin Ⅱ(UⅡ) levels in human cirrhotic populations have been recently shown,but the long-term effects of UⅡ receptor antagonist on the cirrhosis have not been investigated.To investigate the therapeutic effects of urotensin Ⅱ receptor (UT) antagonist palosuran on rats with carbon tetrachloride (CCI4)- induced cirrhosis,the hepatic and systemic hemodynamics,liver fibrosis,the metalloproteinase-13 (MMP-13)/ tissue inhibitor of metalloproteinase-1 (TIMP-1) ratio,hepatic Rho-kinase activity,and the endothelial nitric oxide synthase (eNOS) activity are measured in CCI4-cirrhotic rats treated with palosuran or vehicle for 4 weeks.Primary hepatic stellate cells (HSCs) are used to investigate the changes in UⅡ/UT expression and the in vitro effect of palosuran.Compared with the vehicle-treated cirrhotic rats,treatment with palosuran can reduce the portal pressure (PP),decrease the risk of liver fibrosis and the level of a smooth muscle actin,collagen-l (COL-I),and transforming growth factor β expression.However,treatment with palosuran can increase MMP-13/TIMP-1,pvasodilator- stimulated phosphoprotein (p-VASP),and p-eNOS expression.Moreover,in vitro UⅡ/UT mRNA expression increases during HSC activation.MMP-13/TIMP-1,COL-I,and p-VASP are inhibited after palosuran treatment Our data indicate that long-term administration of palosuran can decrease PP in cirrhosis,which results from decreased hepatic fibrosis and enhanced eNOS-dependent HSC vasodilatation.展开更多
文摘Objective:To comprehensively review the literature relating to the use of Artemisiae Argyi Folium (AAF;the dried leaf of Artemisia argyi Lévl.et Vant.from the Asteraceae family),and qi ai (AAF grown in Qichun County and the adjacent areas in Hubei Province,China) in the field of traditional Chinese medicine.Furthermore,this study aimed to give results of the contents determination of three bioactive components in qi ai and AAF.Methods:The literature was reviewed to acquire relevant information regarding the quality and application of AAF and qi ai.In addition,the contents of the bioactive components (essential oil,total flavonoids and tannins) were determined in 29 AAF samples collected from China and Korea using the methods in the Chinese pharmacopoeia (2015) or determined by our experiments.Results:The dried leaf of A.argyi Lévl.et Vant.from the Asteraceae family is a mainstream commodity of AAF.Qi ai is a commercial type of AAF well-known for its good quality,which has been recorded in Chinese ancient literature.Modern research has showed that more intense heat with stronger penetration was generated in moxibustion therapy when qi ai moxa stick was burnt compared with general moxa stick,which led to a better curative effect.Our research also showed that the contents of essential oil,total flavonoids and tannin in qi ai were significantly higher than those of general AAF samples.Conclusion:The superior quality of qi ai compared with general AAF may be due to relatively higher contents of bioactive components.This study provides basic information for further study and utilization of AAF and qi ai.
基金the National Natural Science Foundation of China (No.81170408 to Diangang Liu)the Wang Baoen Liver Fibrosis Research Foundation of the China Hepatitis Prevention Foundation (No.20120124 to Diangang Liu)the China Postdoctoral Science Foundation (No.2012M510094 to Diangang Liu).
文摘Increased serum urotensin Ⅱ(UⅡ) levels in human cirrhotic populations have been recently shown,but the long-term effects of UⅡ receptor antagonist on the cirrhosis have not been investigated.To investigate the therapeutic effects of urotensin Ⅱ receptor (UT) antagonist palosuran on rats with carbon tetrachloride (CCI4)- induced cirrhosis,the hepatic and systemic hemodynamics,liver fibrosis,the metalloproteinase-13 (MMP-13)/ tissue inhibitor of metalloproteinase-1 (TIMP-1) ratio,hepatic Rho-kinase activity,and the endothelial nitric oxide synthase (eNOS) activity are measured in CCI4-cirrhotic rats treated with palosuran or vehicle for 4 weeks.Primary hepatic stellate cells (HSCs) are used to investigate the changes in UⅡ/UT expression and the in vitro effect of palosuran.Compared with the vehicle-treated cirrhotic rats,treatment with palosuran can reduce the portal pressure (PP),decrease the risk of liver fibrosis and the level of a smooth muscle actin,collagen-l (COL-I),and transforming growth factor β expression.However,treatment with palosuran can increase MMP-13/TIMP-1,pvasodilator- stimulated phosphoprotein (p-VASP),and p-eNOS expression.Moreover,in vitro UⅡ/UT mRNA expression increases during HSC activation.MMP-13/TIMP-1,COL-I,and p-VASP are inhibited after palosuran treatment Our data indicate that long-term administration of palosuran can decrease PP in cirrhosis,which results from decreased hepatic fibrosis and enhanced eNOS-dependent HSC vasodilatation.
